Sermonix Pharmaceuticals Closes US$26 Million Series A Financing Round Led by WILD Family Office
Proceeds will be used to fund Phase 2 ELAINE clinical trial, which is currently enrolling, to develop lasofoxifene as a potential precision medicine for metastatic breast cancer patients with ESR1 mutations. Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology…